Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Total Current Liabilities
All obligations due within one year.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 41.7% from a year ago
Total current liabilities stood at $492.17K at the end of Q1 FY2026, up 41.7% from a year earlier and up 30.8% from the prior quarter.
Context
- Total current liabilities amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +41.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 376.17K USD
- Year-over-year change
- +47177.4%
- 1-year CAGR
- +47177.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 376.17K | +47177.4% |
| FY2024 | 2024-12-31 | 796 | — |
Total Current Liabilities vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's Mar 2026 total current liabilities of $492.17K is the 6th highest of the 10 companies compared; the peer median is $768.22K.
- Its year-over-year change of +41.7% is the 5th highest of 10, against a peer median of +20.8%.
- Total current liabilities amounts to 0.2% of total assets for DMAA, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.85M | +1787.8% | — | 0.8% | |
TACHTitan Acquisition Corp. | Mar 2026 | $1.13M | +138625.5% | — | 0.4% |
TACOUBerto Acquisition Corp. Unit | Mar 2026 | $885.4K | -23.7% | — | 0.3% |
| Mar 2026 | $885.4K | -23.7% | — | 0.3% | |
| Mar 2026 | $768.22K | +1816.1% | — | 0.3% | |
| Mar 2026 | $492.17K | +41.7% | — | 0.2% | |
| Mar 2026 | $340.65K | +138.1% | -57.9% | 0.1% | |
| Mar 2026 | $155.87K | +20.8% | — | 0.1% | |
OYSEOyster Enterprises II Acquisition Corp | Mar 2026 | $141.15K | -28.3% | — | 0.1% |
| Mar 2026 | $107.55K | -82.6% | — | 0.0% | |
| Peer median (excluding DMAA) | $768.22K | +20.8% | -57.9% | 0.3% | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 1.35K | 6.14K |
| Short-term Investments | 0 | 0 |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 0 | 6.05K |
| Total Current Assets | 4.99K | 12.19K |
| Property, Plant & Equipment (Net) | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 546 | 239.91M |
| Total Non-current Assets | 546 | 239.91M |
| Total Assets | 551 | 239.92M |
| Account Payables | 0 | 222.18K |
| Short-term Debt | 662 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 0 |
| Other Current Liabilities | 56 | 0 |
| Total Current Liabilities | 796 | 376.17K |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 0 | 6.9M |
| Total Non-current Liabilities | 0 | 6.9M |
| Total Liabilities | 796 | 7.28M |
| Common Stock | 986 | 239.91M |
| Retained Earnings | (279) | (7.27M) |
| Accumulated OCI | 0 | 0 |
| Other Stockholders Equity | (985) | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (244) | 232.64M |
| Total Debt | 662 | 0 |
| Net Debt | 661 | (6.14K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.